Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma

References

• Meyer RM, Gospodarowicz MK, Connors JM, . Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.
   PubMed Web of Science ®Google Scholar
• Fermé C, Eghbali H, Meerwaldt JH, . Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, . Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, . Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607–614.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Stewart DA, Guo D, Sutherland JA, . Single-agent high-dose melphalan salvage for Hodgkin's disease: cost, safety, and long-term efficacy. Ann Oncol 1997;8:1277–1279.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009;497–506.
   PubMedGoogle Scholar
• Mendler JH, Friedberg JW. Salvage therapy in Hodgkin's lymphoma. The Oncologist 2009;14:425–432.
   PubMed Web of Science ®Google Scholar
• Dunphy FR, Spitzer G, Fornoff JE, . Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994;73:2157–2167.
   PubMed Web of Science ®Google Scholar
• Livingston RB. High-dose cancer therapy without stem cell support-human solid tumors. In: Armitage JO, Antman KH editors. High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Williams and Wilkins: Baltimore;1992. pp 195–210.
   Google Scholar
• Huan SD, Yau JC, Dunphy FR, . Impact of autologous bone marrow infusion on hematopoietic recovery after high dose cyclophosphamide, etoposide and cisplatin. J Clin Oncol 1991;9:1609–1617.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, West W, Tauer K, . Cyclophosphamide, etoposide, cisplatin plus G-CSF (CEP + G) for peripheral blood stem cell (PBSC) mobilization. Proc Annu Meet Am Soc Oncol 1992;11:a1405.
   Google Scholar
• Jennis A, Pecora AL, Isaacs RE, . Dose-intensive cyclophosphamide, etoposide, and platinum (DICEP) as a priming/mobilization regimen for peripheral blood stem cell (PBSC) harvesting prior to high-dose chemotherapy (HDC). Blood 1996;88(Suppl. 1): 404a (Abstr. 1605).
   Google Scholar
• Stewart DA, Guo D, Morris D, . Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999;23:111–117.
   PubMed Web of Science ®Google Scholar
• Stewart DA, Guo D, Glück S, . Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000;26:383–388.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Bagin RG, Jagannath S, . High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993;4:767–773.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete estimations. J Am Stat Assoc 1958;53:457–461.
   Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, . New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002;20:221–230.
   PubMed Web of Science ®Google Scholar
• Bearman SI, Appelbaum FR, Buckner CD, . Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562–1568.
   PubMed Web of Science ®Google Scholar
• Martín A, Fernández-Jiménez MC, Caballero MD, . Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113:161–171.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, . A 2-step comprehensive high-dose chemotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, . Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762–1767.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, . Gemcitabine, vinorelbine, and pegylated liposomal doxorubin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–1079.
   PubMed Web of Science ®Google Scholar
• Fermé C, Mounier N, Diviné M, . Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Group d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002;20:467–475.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Rodriguez MA, Fayad L, . ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999;93:3632–3636.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Nasr F, Bouhris JH, . VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998;21:969–974.
   PubMed Web of Science ®Google Scholar
• Chau I, Harries M, Cunningham D, . Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. Br J Haematol 2003;120:970–977.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Nagy T, Pintillie M, . Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353–360.
   PubMed Web of Science ®Google Scholar
• Moccia A, Hitz F, Hoskins P, Klasa R . Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated out-patient salvage therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). Blood 2010; 116:113a.
   PubMed Web of Science ®Google Scholar
• Josting A, Müller H, Borchmann P, . Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010;28:5074–5080.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Rowlings PA, Zhang M-J, . Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 1999;17:534–545.
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, . Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96:1280–1286.
   PubMed Web of Science ®Google Scholar
• Sureda A, Constans M, Iriondo A, . Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16: 625–633.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Taghipour G, Milligan D, . High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant 1997;20:745–752.
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Mapara M, . Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116–123.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Loberiza Jr FR, Zhang M-J, . Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001;27:387–396.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Metcalfe TL, Gooley TA, . High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma. Cancer 2008;113:1344–1350.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powles R, . Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1312–1319.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Yahalom J, Kewalramani T, . Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934–4937.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Lynch JC, Bociek RG, . The international prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002;13:1370–1377.
   PubMed Web of Science ®Google Scholar
• Czyz J, Dziadziuszko R, Knopinska-Posłuszny W, . Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: analysis of prognostic factors and comparison with a single procedure. Leuk Lymphoma 2007;48:535–541.
   PubMed Web of Science ®Google Scholar
• Smith SM, van Besien K, Carreras J, . Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008;14:904–912.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Brice P, Fermé C, . Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008;26:5980–5987.
   PubMed Web of Science ®Google Scholar